MRD negativity in MM patients correlates with improved survival, suggesting its potential as a surrogate marker for survival outcomes. Novel therapeutics complicate the assessment of PFS and OS, ...

April's vote of the FDA Oncology Drug Advisory Committee to support use of MRD-negative CR as an end point for accelerated approval represents a triumph of science, persistence, and collaboration, ...

Minimal residual disease (MRD) is a key focus in multiple myeloma treatment decision-making, offering prognostic insights and potential treatment guidance. Clinicians use MRD variably, with some ...

MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

At the American Society of Hematology annual meeting, a roundtable discussion highlighted the evolving role of minimal residual disease (MRD) as a treatment endpoint in multiple myeloma, exploring its ...

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...

BOSTON, May 29, 2026--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced the launch of FoundationOne®MRD, a molecular residual disease ...

Myriad Genetics will present new data on its Precise MRD test for renal cell carcinoma at the AACR Annual Meeting. Myriad Genetics, Inc. announced that it will present new clinical data on its Precise ...

SALT LAKE CITY, June 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of ...